How is aleve metabolized

If you have diabetes, you can take ibuprofen, but not too often, because diabetes weakens the kidneys. Be careful if: you have liver damage or any liver disease. The liver metabolizes acetaminophen, and too much can exacerbate liver damage.

Or if you are drinking alcohol. The liver also metabolizes alcohol, so if taken in combination with acetaminophen, it can overwhelm the liver. Details: Ariel Green, a Johns Hopkins resident, says acetaminophen is often her first choice when a patient complains of pain or fever. Be careful if: You have gastrointestinal problems, because naproxen can irritate the stomach lining.

Naproxen sodium is absorbed more rapidly than naproxen formulation. Distribution: Highly protein-bound. It crosses the placental barrier and appears in milk. Metabolism: Metabolized in the liver. Excretion: Excreted in urine. Half-life is 10 to 20 hours. Contraindications and precautions Contraindicated in patients hypersensitive to drug and in those with asthma, rhinitis, or nasal polyps that is precipitated by aspirin or other NSAIDs.

Use cautiously in elderly patients and those with a history of peptic ulcer disease or renal, CV, GI, or hepatic disease. Interactions Drug-drug. Acetaminophen, anti-inflammatories, gold compounds: Increases nephrotoxicity.

Monitor renal function test results. Anticoagulants, thrombolytics, such as coumadin derivatives, heparin, streptokinase, and urokinase: May potentiate anticoagulant effects. Antihypertensives, diuretics: Decreases effects of these drugs. Using together may increase risk of nephrotoxicity. Avoid use together. Anti-inflammatories, corticosteroids, corticotropin, salicylates: May cause increased GI adverse reactions, including ulceration and hemorrhage.

Altogether, the data support the fact that the pharmacokinetics of tenoxicam is related to the genotype of the individuals taking the drug. A considerable amount of data have already been collected concerning the pharmacogenetics of the main metabolic pathways and the major metabolites synthesized for NSAIDs. This, however, is not the case for secondary metabolic pathways and the minor metabolites. The data are very limited and these secondary pathways may seem superficially important; however, this information may be applicable to individuals who are deficient in or have impairment of the metabolizing enzymes for NSAIDs.

It is worth noting that in addition to polymorphisms in metabolizing enzymes, there are additional genetic factors that may contribute to variable drug response among patients.

Clinically, this hepatotoxicity might have been avoided if these genetic markers had been known prospectively before the clinical trials for lumiracoxib were initiated. Of note, pharmacogenetics is but one patient characteristic, in addition to age, sex, past medical history and other concomitant pharmacotherapy that have to be accounted for when dealing with patients. NSAIDs are widely used with over 30 million daily users who depend on this class of medications that permits these patients to have relief from the respective ailments that are plaguing them.

With the advent of the Human Genome Project, there is a new standard that should be sought for understanding how genetic differences in cytochrome enzymes affect the clearance of NSAIDs. The goal of collecting these data is to optimize patient care by selecting effective NSAIDs for each individual, utilizing this class of medications in lieu of analgesics that are either harmful for the patient or ineffective at reducing the pain level experienced by the patient.

However, based upon some of the examples described throughout the article, there appears to be a considerable amount of research, such as retrospective studies modeled after Singer et al. These types of studies would help identify associations between genetic markers and adverse effects for patients. In conclusion, pharmacogenetics is just one tool that should be employed to continue the improvement of patient care by providing analgesia or minimization of pain while avoiding serious side effects such as renal, cardiovascular and gastrointestinal effects.

Pharmacogenetics of anesthetic and analgesic agents. Anesthesiology ; : — Ma Q, Lu AY. Pharmacogenetics, pharmacogenomics, and individualized medicine.

Pharmacol Rev ; 63 : — McGraw-Hill: New York, Google Scholar. A map of human genome sequence variation containing 1. Nature ; : — The importance of including topics related to pharmacogenetics, pharmacogenomics, and medical genetics in the pharmacy curriculum. Am J Pharm Educ ; 73 : Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis.

Nonsteroidal anti-inflammatory drugs and heart failure. Drugs ; 63 : — Functional characterization of cyclooxygenase-2 polymorphisms.

J Pharmacol Exp Ther ; : — Cyclooxygenase-2 polymorphisms and risk of rheumatoid arthritis in Koreans. J Rheumatol ; 35 : — Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. Harirforoosh S, Jamali F. Renal adverse effects of nonsteroidal anti-inflammatory drugs. Expert Opin Drug Saf ; 8 : — Whelton A, Hamilton CW. Nonsteroidal anti-inflammatory drugs: effects on kidney function. J Clin Pharmacol ; 31 : — Cyclooxygenase 2 and the kidney.

Curr Opin Nephrol Hypertens ; 10 : 89— Stamer UM, Stuber F. The pharmacogenetics of analgesia. Expert Opin Pharmacother ; 8 : — Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis. Pharmacogenetics ; 10 : — The role of CYP2C9 genotype in the metabolism of diclofenac in vivo and in vitro.

Eur J Clin Pharmacol ; 57 : — Drug Metab Dispos ; 30 : — Expert Opin Drug Metab Toxicol ; 5 : — Cytochrome P 2C9 polymorphisms: a comprehensive review of the in-vitro and human data. Pharmacogenetics ; 12 : — Liao JK. Safety and efficacy of statins in Asians. Am J Cardiol ; 99 : — American Society of Hospital Pharmacists. Clinical drugs undergoing polymorphic metabolism by human cytochrome P 2C9 and the implication in drug development. Curr Med Chem ; 18 : — Celecoxib inhibits metabolism of cytochrome P 2D6 substrate metoprolol in humans.

Naproxen sodium Anaprox is a potent antiinflammatory and analgesic agent. The drug has demonstrated a variety of biologic actions, including stabilization of lysosomal membranes, but most of its therapeutic activity is probably mediated through prostaglandin synthesis inhibition.

The linkage between inhibition of prostaglandin synthesis and relief of dysmenorrhea has been documented in clinical studies, reported elsewhere in this supplement.

Of relevance is the selective activity of naproxen sodium on uterine microsomal preparations.